Market Cap 2.76B
Revenue (ttm) 190.41M
Net Income (ttm) 20.89M
EPS (ttm) N/A
PE Ratio 29.94
Forward PE 14.46
Profit Margin 10.97%
Debt to Equity Ratio 0.10
Volume 4,968,800
Avg Vol 3,907,030
Day's Range N/A - N/A
Shares Out 52.12M
Stochastic %K 100%
Beta -2.22
Analysts Hold
Price Target $53.00

Company Profile

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 20...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 213 8444
Fax: 650 213 8383
Website: soleno.life
Address:
100 Marine Parkway, Suite 400, Redwood City, United States
PeterRaslow
PeterRaslow Jun. 1 at 9:19 PM
$ABVX bought at $130 and out now, can't stomach this, another $SLNO
1 · Reply
ObserverExplorer
ObserverExplorer May. 21 at 6:05 AM
It is $ALT After its phase 2 and I happened to be at the right spot coming out of $SLNO, October 2023, entered ALT at 2.45. It's phase 2 result was Success and it shot up to $14 but the GREED kept me because of all the hype to go up and the BUYOUT thesis. Today ALT trade at 2.89. The company is good, so is the product. Hopefully, it will deliver at Phase 3 but atleast I, as a retail investor don't want to hold over 1-2 year. For long term there is Always S&P 500 or equivalent. So, I say be wise of words like "Buyout". If you made good enough, "EXIT" is the right word. 😊🙏.
1 · Reply
NVDAMillionaire
NVDAMillionaire May. 19 at 11:14 PM
$SLNO Outstanding article that hits the mark on SLNO's current state. So if you want to refresh your SLNO insights or learn about SLNO from scratch, this is a must read. https://everyticker.com/quote/SLNO/analysis/soleno-s-2-9b-validation-why-neurocrine-is-paying-53-for-a-drug-that-didn-t-exist-18-months-ago-nasdaq-slno
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 17 at 2:17 AM
$KALV filed their 14D9 with the SEC last Wednesday. The filing includes, among other things, the financial projection provided Chiesi that of course included an Eckterly revenue forecast. The attachment compares the revenue forecast prepared by KALV mgmt/BOD to analyst consensus revenue estimates per Seeking Alpha. KALV's mgmt/BOD prepared 5 & 10-year revenue forecast was roughly 10% lower than analysts. We recall $SLNO mgmt/BOD prepared revenue forecast was lower but it's our experience the variance is usually the other way around. This also means the revenue multiples paid were higher. The SLNO 5-year multiple was 0.70 where KALV's was 1.02X. KALV projected a gross margin of 87.4% over the first 10 years of Eckterly's launch. As always, this is not investment advice. We're merely sharing analysis. $XBI $IBB
1 · Reply
TwongStocks
TwongStocks May. 14 at 10:31 AM
$SLNO Equity Corporate Actions Alert #2026 - 322 Information Regarding the Tender Offer of Soleno Therapeutics, Inc. (SLNO) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-322 The tender offer by a subsidiary of Neurocrine Biosciences to acquire all of the outstanding common stock of Soleno Therapeutics, Inc. (SLNO) is scheduled to expire one minute following 11:59 p.m. ET, on May 15, 2026. The subsequent merger is tentatively scheduled to close prior to the market open on May 18, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 15, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 18th) and will be suspended effective May 19, 2026. SLNO shareholders will receive $53 per share at closing.
0 · Reply
11thestate
11thestate May. 4 at 3:21 PM
$SLNO investors: there is a new securities class action filed against Soleno Therapeutics over hiding safety problems tied to DCCR, including fluid retention and other adverse-event risks seen in trials and after launch. If you held shares between March 26, 2025, and November 4, 2025, you can join the case and track recovery here https://11th.com/cases/solenotherapeutics-investor-suit Lead plaintiff deadline: May 5, 2026. Anyone else holding?
0 · Reply
PhishTourFunds
PhishTourFunds May. 1 at 3:00 AM
$SLNO Wyckoff and a reversal on the one year 👀
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 5:52 PM
$SLNO Current Stock Price: $52.77 Contracts to trade: $55.0 SLNO May 15 2026 Call Entry: $0.04 Exit: $0.07 ROI: 84% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Bahamuttheking
Bahamuttheking Apr. 28 at 5:19 PM
$SLNO so idk whats the play do i take the $53 per share and what happens if i dont?
0 · Reply
Chrissixdd
Chrissixdd Apr. 25 at 2:50 PM
been digging through the industry and $SLNO is in the cheaper bucket. $RCKT $ORIC $CLYM $DNA nearby too
0 · Reply
Latest News on SLNO
Neurocrine to Buy Soleno for $2.9 Billion

Apr 6, 2026, 7:34 AM EDT - 2 months ago

Neurocrine to Buy Soleno for $2.9 Billion

NBIX


Neurocrine to buy Soleno Therapeutics for $2.9 billion

Apr 6, 2026, 7:07 AM EDT - 2 months ago

Neurocrine to buy Soleno Therapeutics for $2.9 billion

NBIX


Soleno Therapeutics Slides: Corporate presentation

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Soleno Therapeutics Slides: Corporate presentation


Soleno Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Soleno Therapeutics Earnings Call Transcript: Q4 2025


Soleno Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Soleno Therapeutics Annual report: Q4 2025


Soleno Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Soleno Therapeutics Earnings release: Q4 2025


Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm

Nov 12, 2025, 10:56 AM EST - 7 months ago

Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm


Soleno Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Soleno Therapeutics Earnings Call Transcript: Q3 2025


Soleno Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Soleno Therapeutics Quarterly report: Q3 2025


Soleno Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Soleno Therapeutics Earnings release: Q3 2025


Soleno Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Soleno Therapeutics Earnings Call Transcript: Q2 2025


Soleno Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Soleno Therapeutics Quarterly report: Q2 2025


Soleno Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Soleno Therapeutics Earnings release: Q2 2025


PeterRaslow
PeterRaslow Jun. 1 at 9:19 PM
$ABVX bought at $130 and out now, can't stomach this, another $SLNO
1 · Reply
ObserverExplorer
ObserverExplorer May. 21 at 6:05 AM
It is $ALT After its phase 2 and I happened to be at the right spot coming out of $SLNO, October 2023, entered ALT at 2.45. It's phase 2 result was Success and it shot up to $14 but the GREED kept me because of all the hype to go up and the BUYOUT thesis. Today ALT trade at 2.89. The company is good, so is the product. Hopefully, it will deliver at Phase 3 but atleast I, as a retail investor don't want to hold over 1-2 year. For long term there is Always S&P 500 or equivalent. So, I say be wise of words like "Buyout". If you made good enough, "EXIT" is the right word. 😊🙏.
1 · Reply
NVDAMillionaire
NVDAMillionaire May. 19 at 11:14 PM
$SLNO Outstanding article that hits the mark on SLNO's current state. So if you want to refresh your SLNO insights or learn about SLNO from scratch, this is a must read. https://everyticker.com/quote/SLNO/analysis/soleno-s-2-9b-validation-why-neurocrine-is-paying-53-for-a-drug-that-didn-t-exist-18-months-ago-nasdaq-slno
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 17 at 2:17 AM
$KALV filed their 14D9 with the SEC last Wednesday. The filing includes, among other things, the financial projection provided Chiesi that of course included an Eckterly revenue forecast. The attachment compares the revenue forecast prepared by KALV mgmt/BOD to analyst consensus revenue estimates per Seeking Alpha. KALV's mgmt/BOD prepared 5 & 10-year revenue forecast was roughly 10% lower than analysts. We recall $SLNO mgmt/BOD prepared revenue forecast was lower but it's our experience the variance is usually the other way around. This also means the revenue multiples paid were higher. The SLNO 5-year multiple was 0.70 where KALV's was 1.02X. KALV projected a gross margin of 87.4% over the first 10 years of Eckterly's launch. As always, this is not investment advice. We're merely sharing analysis. $XBI $IBB
1 · Reply
TwongStocks
TwongStocks May. 14 at 10:31 AM
$SLNO Equity Corporate Actions Alert #2026 - 322 Information Regarding the Tender Offer of Soleno Therapeutics, Inc. (SLNO) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-322 The tender offer by a subsidiary of Neurocrine Biosciences to acquire all of the outstanding common stock of Soleno Therapeutics, Inc. (SLNO) is scheduled to expire one minute following 11:59 p.m. ET, on May 15, 2026. The subsequent merger is tentatively scheduled to close prior to the market open on May 18, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 15, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 18th) and will be suspended effective May 19, 2026. SLNO shareholders will receive $53 per share at closing.
0 · Reply
11thestate
11thestate May. 4 at 3:21 PM
$SLNO investors: there is a new securities class action filed against Soleno Therapeutics over hiding safety problems tied to DCCR, including fluid retention and other adverse-event risks seen in trials and after launch. If you held shares between March 26, 2025, and November 4, 2025, you can join the case and track recovery here https://11th.com/cases/solenotherapeutics-investor-suit Lead plaintiff deadline: May 5, 2026. Anyone else holding?
0 · Reply
PhishTourFunds
PhishTourFunds May. 1 at 3:00 AM
$SLNO Wyckoff and a reversal on the one year 👀
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 5:52 PM
$SLNO Current Stock Price: $52.77 Contracts to trade: $55.0 SLNO May 15 2026 Call Entry: $0.04 Exit: $0.07 ROI: 84% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Bahamuttheking
Bahamuttheking Apr. 28 at 5:19 PM
$SLNO so idk whats the play do i take the $53 per share and what happens if i dont?
0 · Reply
Chrissixdd
Chrissixdd Apr. 25 at 2:50 PM
been digging through the industry and $SLNO is in the cheaper bucket. $RCKT $ORIC $CLYM $DNA nearby too
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 24 at 1:57 AM
It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 21 at 5:24 PM
$SLNO filed its Form 14D9 with the SEC yesterday that included, among other things, the revenue forecast prepared by SLNO mgmt/BOD & provided to $NBIX. We find the discrepancy between SLNO analyst consensus & SLNO mgmt/BOD to be stunning. This highlights the enormous risk relying on analyst consensus when guesstimating potential M&A exit valuations. Attached are screenshots of SLNO analyst consensus per Seeking Alpha as of the morning the acquisition was announced (4/6/26) and SLNO's 14D9 filing from yesterday. The 2nd attachment provides the differences by year between SLNO analyst consensus & the revenue forecast provided by SLNO mgmt/BOD. Note 5-year analyst estimates were 32% higher than SLNO mgmt/BOD. 10-year revenues were 50% higher. The flip side is it appears the $2.444B enterprise value paid was priced @ 0.70X 5-year revenues & 0.28X 10-year revenues. FWIW it's our experience peer comm'l-stage M&A exits are priced at 0.90 to 1.05X 5-year & 0.30 to 0.40X 10-year $XBI $IBB $PFE ?
1 · Reply
anachartanalyst
anachartanalyst Apr. 17 at 2:02 PM
$SLNO https://anachart.com/wp-content/uploads/ana_temp/1776434501_soc-img.jpg
0 · Reply
theoptionsplug
theoptionsplug Apr. 17 at 4:42 AM
THINGS TO WATCH, FRIDAY, 4/17/26 👁️ $ALLY $BA $SLNO $SPY $QQQ
0 · Reply
dennismccain
dennismccain Apr. 11 at 3:10 AM
$SLNO About five weeks ago I posted this comment (see below) about this biotech company because its stock that had recently showed up on my list of growth stocks at a reasonable price. I’ve never really been comfortable or successful investing in biotech stocks, so I passed on the idea. Unfortunately for me that was a bad idea. The company recently announced that it was being bought out by another company at a very nice premium. I bring this whole thing up because regardless of my personal biases, likes, and dislikes, that list continues to identify fast growing, yet undervalued, companies. In this case another company recognized that value that I ignored and bought out the entire company. If I had bought those shares my ROI would have been about 50% for holding the shares for just 5 weeks.
0 · Reply
Ooil
Ooil Apr. 8 at 9:01 PM
$IFRX Have a look at $SLNO that back in 2022 was a $1 ticket, 2023 at $5 and early 2024 close to $50. Soleno just bought out in a $2.9B deal. Soleno had an exceptional P3 in an orphan disease and was heavily shorted. And we all know that InflaRx late breaker presentation in PG shows everything but futility and also orphan. Whats the new p value in PG again? How many shares shorted?
1 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 8 at 5:51 AM
$SLNO see you at 75
0 · Reply
MikiTrader
MikiTrader Apr. 8 at 5:24 AM
$SLNO Yeah, I think people made a really good call. Not just me.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 8 at 1:13 AM
The 1st attachment shows the collective $NBIX & $SLNO analyst consensus revenue ests as of the morning the M&A exit was announced incl highest analyst est, consensus, lowest analyst est, consensus excl the highest analyst est, & consensus excl both the highest & lowest analyst est. At the bottom we simply add the 2 together for an idea of what NBIX analyst ests may, again may, look like post M&A. We then show a "what-if" NBIX was acquired for a peer 0.35X multiple on 10-year collective consensus just for fun. This may be absurd considering SLNO exited at a 0.15X 10-year multiple. The graph compares the collective NBIX/SLNO 10-year analyst consensus & an assumed gross margin @ 97% (NBIX actual FY25 gross margin = 97%, SLNO = 99%) v. the actual 10-year revenue & gross margin projection prepared by $SGEN when SGEN was acquired for an EV of $42B. SGEN provided a 12 year forecast (projecting peak sales in Year 10). Compare NBIX/SLNO 10 year gross margin (even if too high) to SGEN $XBI $IBB
1 · Reply
Stockanuck
Stockanuck Apr. 7 at 6:00 PM
$UNH $SLNO $IBRX $SRPT $LLY Among these big five calls, there was a call option trade with bullish sentiment. It expires in 17 day(s) on April 24, 2026. Parties traded 25 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $1800.0 per contract. There were 4001 open contracts at this strike prior to today, and today 3958 contract(s) were bought and sold. 9 Health Care Stocks With Whale Alerts In Today's Session https://www.benzinga.com/insights/options/26/04/51687681/9-health-care-stocks-with-whale-alerts-in-todays-session
0 · Reply